Resources

In this Exclusive Interview, Dr. Aaron Kowalski talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the meaning of his role as Chief Mission Officer and the work being funded to not only advance the cause of curing type 1 diabetes one day in the unknown future, but the work toward improving the quality of life for these people today.

In part 2 of this Exclusive Interview, Dr. Aaron Kowalski talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the personal impact of diabetes on his own life and defining what a diabetes cure could mean to different people.

In part 1 of this Exclusive Interview, Dr. Aaron Kowalski talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about his role at the JDRF and the studies getting their support.

In part 3 of this Exclusive Interview, Dr. Aaron Kowalski talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about exciting research applicable to health care professionals.

In part 4, the conclusion of this Exclusive Interview, Dr. Aaron Kowalski talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about his ideal A1C and the #1 benefit of the hybrid closed loop system.

I traveled to Europe, a continent with a lot of history and cobblestone streets. I was aware of the amount of walking I was going to do and reminded myself of what we teach, or should be teaching, our patients: Do not travel with new shoes only. Always bring a pair of tried and true. And when you do buy new shoes, buy them later in the day, make sure they fit well, and break them in before wearing for long periods at a time. Wear them about a half hour a day, then slowly increase the time you wear your shoes to avoid foot problems.

In part 6 of this Exclusive Interview, Dr. Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the ability to predict cardiovascular disease.

In this week's Homerun Slides, the technology currently and soon to be helping people to manage their diabetes.

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver disease ranging from simple liver fat accumulation to severe hepatic necro-inflammation (nonalcoholic steatohepatitis or NASH), and eventually cirrhosis.

Patients with type 2 diabetes usually do not die from diabetes, but from cardiovascular disease and strokes.